Dossier assessment

Ublituximab (multiple sclerosis) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A24-13
Last updated

Report documents

  1. Extract of dossier assessment

    Ublituximab (multiple sclerosis) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 377 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A24-13_en
  2. Dossier assessment

    Ublituximab (multiple sclerosis) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 618 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A24-13

Dossier assessment

Indication:

Adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features

Result of dossier assessment:
  • Patients who have not yet received disease-modifying therapy and show no evidence of a severe course of disease: added benefit not proven
  • Patients who have not yet received disease-modifying therapy and show evidence of a severe course of disease and adults who show an active course of disease despite treatment with a disease-modifying therapy: added benefit not proven

Additional information

Federal Joint Committee (G-BA)

01-08-2024 A G-BA decision was published.
G-BA documents on this decision

Project details

Project no.
A24-13
Commission
Commission awarded on 30.01.2024 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Immune system and infections
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A24-13_en

Connected Projects

  1. Addendum

    Ublituximab (multiple sclerosis) – 2nd Addendum to Project A24-13

    Project no.
    G24-14
    Last updated

    Status: Commission completed

  2. Addendum

    Ublituximab (multiple sclerosis) – Addendum to Project A24-13

    Project no.
    A24-68
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form